Provided by Tiger Trade Technology Pte. Ltd.

Benitec Biopharma

13.48
+0.47003.61%
Post-market: 13.480.00000.00%19:30 EDT
Volume:160.14K
Turnover:2.19M
Market Cap:461.76M
PE:-14.44
High:13.98
Open:13.14
Low:13.03
Close:13.01
52wk High:16.76
52wk Low:9.85
Shares:34.25M
Float Shares:17.93M
Volume Ratio:0.78
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9338
EPS(LYR):-1.0472
ROE:-29.58%
ROA:-19.93%
PB:2.52
PE(LYR):-12.87

Loading ...

Benitec Biopharma Initiated at Outperform by Wedbush

Dow Jones
·
Jul 28

Benitec Biopharma Inc : Wedbush Initiates Coverage with Outperform Rating; Target Price $16

THOMSON REUTERS
·
Jul 28

Wedbush Initiates Benitec Biopharma at Outperform With $16 Price Target

MT Newswires Live
·
Jul 28

Novartis Receives European Commission Approval for Itvisma® for Spinal Muscular Atrophy (SMA)

Reuters
·
Jul 07

Novartis Receives European Commission Approval for Itvisma® for Spinal Muscular Atrophy (SMA)

Reuters
·
Jul 02

Benitec Biopharma downgraded to Neutral from Buy at Guggenheim

TIPRANKS
·
Jun 10

Benitec Biopharma Announces Board Changes and New Director

TIPRANKS
·
May 30

BRIEF-Benitec Biopharma - CFO Megan Boston Resigns From Board Effective May 22, 2026

Reuters
·
May 30

Benitec Biopharma - Megan Boston to Continue as Chief Financial Officer and Secretary - SEC Filing

THOMSON REUTERS
·
May 30

Benitec Biopharma files Form 3 for director David Matthew Friedman

Reuters
·
May 29

Benitec Biopharma posts BB-301 gene therapy update for OPMD-related dysphagia

Reuters
·
May 16

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 15

Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia

TIPRANKS
·
May 15

Benitec Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Benitec Biopharma Q3 EPS $(0.24) Beats $(0.27) Estimate

Benzinga Earnings
·
May 14

Benitec Biopharma Q3 net loss narrows as expenses fall

Reuters
·
May 14

Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update

THOMSON REUTERS
·
May 14

Benitec Biopharma Inc - Cash and Cash Equivalents $184.8 Mln as of March 31, 2026

THOMSON REUTERS
·
May 14

Benitec Biopharma Inc - on Track to Engage With FDA Mid-Year to Formalize Bb-301 Pivotal Study Design

THOMSON REUTERS
·
May 14

Benitec Biopharma Q3 Operating Income USD -13.6 Million

THOMSON REUTERS
·
May 14